CByond

CByond is a clinical-stage biotechnology company specializing in the development of next-generation Tumor-Infiltrating Lymphocyte (TIL) therapies for the treatment of solid tumors. Originating from the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center, the company leverages advanced cell expansion and selection technologies to enhance the potency and persistence of TILs. Their lead programs focus on metastatic melanoma, where they aim to provide curative options for patients who have failed standard checkpoint inhibitor therapies. CByond's approach integrates deep clinical expertise with proprietary manufacturing processes to optimize the therapeutic potential of the patient's own immune system. The company is positioned at the forefront of personalized cell therapy, bridging the gap between academic research and commercial-scale production.